The USFDA has recently granted emergency use authorization to the first antigen-based diagnostic test for COVID-19, which is included as a new category of coronavirus diagnostics tests. The aim of this is to step up the rapid diagnosis of suspected patients. The body of a COVID-19 infected patient responds to the viral infection immediately as a part of a non-specific innate response. As a part of the phenomenon, macrophages, neutrophils, and dendritic cells slow the progress of the virus.
This may result in causing asymptomatic manifestations. Such asymptomatic patients with COVID-19 carry the virus with them and act as potential sources of infection. This can be controlled through rapid testing, enabling early diagnosis and management of the disease. Previously, the USFDA had authorized two categories of COVID-19 diagnostics test, viz., polymerase chain reaction (PCR) test, and…
